Anu Connor
Vice President, Head of Oncology Search & Evaluation Ipsen Pharma
Anu Connor is Vice President, Head of Oncology External Innovation at Ipsen. In her current role, Anu and her team work closely with key scientific, clinical, and commercial functions to identify and evaluate external opportunities in oncology, both in solid tumors and hematologic malignancies, that are a strategic fit for Ipsen’s portfolio. Prior to her role at Ipsen, Anu led the Hematology Search and Evaluation Business Development team at BMS. Prior to BMS, Anu led Due Diligence, Search and Evaluation activities in the NIBR BD&L organization at Novartis. Prior to her transition to search and evaluation, Anu had roles in the toxicology/translational medicine organizations at Genentech/Roche and Novartis.
Seminars
- The pharma icebreaker tables running in each track create introductions between biotech and pharma
- Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selection to meet with companies they haven’t scheduled meetings with yet through the One-to-One Partnering Portal
- With these selections, we will build a schedule of company rotations through each pharma’s table
- Join three tables, led by three pharma, for 30 minutes each. Mixed groups rather than 1-2-1s, hear how your peers pitch themselves whilst also getting facetime with pharma yourself, first thing on day one
- Understanding what it takes for pharma to invest. What are the current budgetary considerations within pharma?
- How is pharma assessing novel technologies, and where do they place within portfolios?
- What feels differentiated in a crowded space? From pharma’s perspective, what will make something best-in-class?
